Evaluation of Thalidomide for Treatment or Prevention of Chronic Graft-versus-host Disease

References

• Zhang, Y, McCormick, Li., Desai, SR., Wu, C. and Gilliam, A.C. (2002) "Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation", J. Immunol. 168, 3088–3098.
   PubMed Web of Science ®Google Scholar
• Zorat, F., Shetty, V., Dutt, D., et al. (2001) "The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes", Br J. Haematol. 115, 881–894.
   PubMed Web of Science ®Google Scholar
• Wood, P.M. and Proctor, S.J. (1990) "The potential use of thalidomide in the therapy of graft-versus-host disease—a review of clinical and laboratory information (Review)", Leuk. Res. 14, 395–399.
   PubMed Web of Science ®Google Scholar
• Iyer, C.G., Languillon, J., Ramanujam, K., et al. (1991) "WHO co-ordinated short-term double blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients", Bull. WHO 45, 719–732.
   Google Scholar
• Hellmann, K. (1966) "Immunosuppression by thalidomide: implications for teratology", Lancet 1, 1136–1137.
   PubMed Web of Science ®Google Scholar
• Barnhill, R.L. and McDougall, A.C. (1982) "Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions", J. Am. Acad. Dennatol. 7, 317–323.
   PubMed Web of Science ®Google Scholar
• DeKlerk, J.N., Murphy, G.P., Van Zyl, J.J., et al. (1969) "New methods of treatment for renal allotransplants using the baboon as a primate experimental model", J. Urol. 102, 532–540.
   PubMed Web of Science ®Google Scholar
• Uthoff, K., Zehr, K.J., Gaudin, P.B., et al. (1995) "Thalidomide as replacement for steroids in immunosuppression after lung transplantation", Ann. Thorac. Surg. 59, 277–282.
   PubMed Web of Science ®Google Scholar
• Field, E.O., Gibbs, J.E., Tucker, D.F. and Hellmann, K. (1966) "Effect of thalidomide on the graft versus host reaction", Nature 211, 1308–1310.
   PubMed Web of Science ®Google Scholar
• Vogelsang, GB., Hess, A.D., Gordon, G. and Santos, G.W. (1986) "Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model", Transplantation 41, 644–647.
   PubMed Web of Science ®Google Scholar
• Vogelsang, GB., Wells, M.C., Santos, G.W., Chen, T.L. and Hess, A.D. (1988) "Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model", Transplant. Proc. 20, 226–228.
   PubMed Web of Science ®Google Scholar
• Vogelsang, GB., Hess, A.D., Gordon, G., Brundrette, R. and Santos, G.W. (1987) "Thalidomide induction of bone marrow transplantation tolerance", Transplant. Proc. 19, 2658–2661.
   PubMed Web of Science ®Google Scholar
• Vogelsang, GB., Hess, A.D. and Santos, G.W. (1988) "Thalidomide for treatment of graft-versus-host disease (Review)", Bone Marrow Transplant. 3, 393–398.
   PubMed Web of Science ®Google Scholar
• Heney, D., Norfolk, DR., Wheeldon, J., Bailey, C.C., Lewis, I.J. and Barnard, D.L. (1991) "Thalidomide treatment for chronic graft-versus-host disease", Br J. Haematol. 78, 23–27.
   PubMed Web of Science ®Google Scholar
• Vogelsang, GB., Farmer, ER., Hess, AD., et al. (1992) "Thalidomide for the treatment of chronic graft versus host disease", N. Engl. J. Med. 326, 1055–1058.
   PubMed Web of Science ®Google Scholar
• Cole, C.H., Rogers, P.C., Pritchard, S., Phillips, G. and Chan, K.W. (1994) "Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation", Bone Marrow Transplant. 14, 937–942.
   PubMed Web of Science ®Google Scholar
• Parker, P.M., Chao, N., Nademanee, A., et al. (1995) "Thalidomide as salvage therapy for chronic graft-versus-host disease", Blood 86, 3604–3609.
   PubMed Web of Science ®Google Scholar
• Rovelli, A., Arrigo, C., Nesi, F., et al. (1998) "The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children", Bone Marrow Transplant. 21, 577–581.
   PubMed Web of Science ®Google Scholar
• Browne, P.V., Weisdorf, D.J., DeFor, T., et al. (2000) "Response to thalidomide therapy in refractory chronic graft-versus-host disease", Bone Marrow Transplant. 26, 865–869.
   PubMed Web of Science ®Google Scholar
• Rajkumar, S.V. (2001) "Current status of thalidomide in the treatment of cancer (Review)", Oncology (Huntingt.) 15, 867–874.
   PubMed Web of Science ®Google Scholar
• Schumacher, H., Smith, R.L. and Williams, R.T. (1965) "The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species", Br. J. Phannacol. 25, 338–351.
   Web of Science ®Google Scholar
• Schumacher, H., Smith, R.L. and Williams, R.T. (1965) "The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution", Br J. Phannacol. 25, 324–337.
   Web of Science ®Google Scholar
• Sampaio, E.P., Kaplan, G., Miranda, A., et al. (1993) "The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum", J. Infect. Dis. 168, 408–414.
   PubMed Web of Science ®Google Scholar
• Sarno, EN., Grau, G.E., Vieira, L.M. and Nery, J.A. (1991) "Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states", Clin. Exp. Immunol. 84, 103–108.
   PubMed Web of Science ®Google Scholar
• Sampaio, E.P., Moreira, A.L., Sarno, EN., Malta, A.M. and Kaplan, G. (1992) "Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients", J. Exp. Med. 175, 1729–1737.
   PubMed Web of Science ®Google Scholar
• Sampaio, E.P., Sarno, EN., Galilly, R., Cohn, Z.A. and Kaplan, G. (1991) "Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes", J. Exp. Med. 173, 699–703.
   PubMed Web of Science ®Google Scholar
• Nogueira, AC., Neubert, R., Helge, H. and Neubert, D. (1994) "Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells", Life Sci. 55, 77–92.
   PubMed Web of Science ®Google Scholar
• Jacobson, J.M., Greenspan, J.S., Spritzler, J., et al. (1997) "Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trails Group", N. Engl. J. Med. 336, 1487–1493.
   PubMed Web of Science ®Google Scholar
• McHugh, S.M., Rifkin, I.R., Deighton, J., et al. (1995) "The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Thl cytokine production in mitogen- and antigen-stimulated human peripheral blood mono-nuclear cell cultures", Clin. Exp. Immunol. 99, 160–167.
   PubMed Web of Science ®Google Scholar
• Hastings, R.C. (1980) "Kellersberger Memorial Lecture: immuno-suppressive/anti-inflammatory thalidomide analogues", Ethiop. Med. J. 18, 65–71.
   PubMedGoogle Scholar
• D'Amato, R.J., Loughnan, MS., Flynn, E. and Folkman, J. (1994) "Thalidomide is an inhibitor of angiogenesis", Proc. Natl Acad. Sci. USA 91, 4082–4085.
   PubMed Web of Science ®Google Scholar
• Argiles, J.M., Carbo, N. and Lopez-Soriano, F.J. (1998) "Was tumour necrosis factor-alpha responsible for the fetal malforma-tions associated with thalidomide in the early 1960s? (Review)", Med. Hypotheses 50, 313–318.
   PubMed Web of Science ®Google Scholar
• Parman, T., Wiley, M.J. and Wells, PG. (1999) "Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity", Nat. Med. 5, 582–585.
   PubMed Web of Science ®Google Scholar
• Vogelsang, GB., Hess, A.D., Friedman, K.J. and Santos, G.W. (1989) "Therapy of chronic graft-v-host disease in a rat model", Blood 74, 507–511.
   PubMed Web of Science ®Google Scholar
• Arora, M., Wagner, J.E., Davies, S.M., et al. (2001) "Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease", Biol. Blood Marrow Transplant. 7, 265–273.
   PubMed Web of Science ®Google Scholar
• Koc, S., Leisenring, W., Flowers, MED., et al. (2000) "Thalidomide for treatment of patients with chronic graft-versus-host disease", Blood 96, 3995–3996.
   PubMed Web of Science ®Google Scholar
• Chen, T.L., Vogelsang, GB., Petty, B.G., et al. (1989) "Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers", Drug Metab. Dispos. 17, 402–405.
   PubMed Web of Science ®Google Scholar
• Chao, N.J., Parker, P.M., Niland, J.C., et al. (1996) "Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease", Biol. Blood Marrow Transplant. 2, 86–92.
   PubMedGoogle Scholar